Amiodarone for prevention of atrial fibrillation following esophagectomy
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved..
OBJECTIVES: Atrial fibrillation (AF) is a common complication after esophagectomy and is associated with symptoms, hemodynamic instability, prolonged hospital stay, and an increased incidence of mortality. Our objective was to determine the efficacy and safety of intravenous amiodarone for prophylaxis of postesophagectomy AF.
METHODS: In this retrospective cohort study, 309 patients who underwent esophagectomy formed the initial cohort. Following propensity score-matching, 110 patients who received prophylactic amiodarone 43.75 mg/hour via continuous intravenous infusion over 96 hours (total dose, 4200 mg) were matched to a control group of patients who did not undergo amiodarone prophylaxis (n = 110). The propensity score was obtained using a multivariate logistic regression model with amiodarone as the variable and the following covariates: age, sex, surgical approach, history of neoadjuvant chemotherapy and/or radiation, chronic obstructive pulmonary disease, heart failure, cardiovascular disease, alcohol use (>7 drinks/week), preadmission β-blockers discontinued during hospitalization, preoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, preoperative use of corticosteroids, postoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, postoperative use of corticosteroids, postoperative use of statins, and preoperative Charlson comorbidity index.
RESULTS: The incidence of AF requiring treatment due to rapid ventricular rate and symptoms was lower in the amiodarone group (17 out of 110 [15.5%] vs 32 out of 110 [29.1%]; odds ratio, 0.45; 95% confidence interval, 0.23-0.86; P = .015). There were no significant differences between the groups in median postoperative length of hospital stay, incidence of pulmonary complications, or mortality. The incidences of hypotension requiring treatment (42.7% vs 21.8%; P = .001), bradycardia (8.2% vs 0.0%; P = .002), and corrected QT interval prolongation (10.9% vs 0.0%; P ≤ .0001) were significantly higher in the amiodarone group.
CONCLUSIONS: Prophylactic intravenous amiodarone is associated with a reduction in the incidence of AF following esophagectomy, but is not associated with shorter postoperative length of hospital stay. Intravenous amiodarone for prophylaxis of postesophagectomy AF is associated with hypotension, bradycardia, and corrected QT interval prolongation.
| Errataetall: |
CommentIn: J Thorac Cardiovasc Surg. 2019 Jul;158(1):311-312. - PMID 30876664 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
The Journal of thoracic and cardiovascular surgery - 158(2019), 1 vom: 04. Juli, Seite 301-310.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tisdale, James E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amiodarone |
|---|
| Anmerkungen: |
Date Completed 25.02.2020 Date Revised 25.02.2020 published: Print-Electronic CommentIn: J Thorac Cardiovasc Surg. 2019 Jul;158(1):311-312. - PMID 30876664 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtcvs.2019.01.095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294769463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294769463 | ||
| 003 | DE-627 | ||
| 005 | 20231225082213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtcvs.2019.01.095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0982.xml |
| 035 | |a (DE-627)NLM294769463 | ||
| 035 | |a (NLM)30853230 | ||
| 035 | |a (PII)S0022-5223(19)30309-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tisdale, James E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amiodarone for prevention of atrial fibrillation following esophagectomy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.02.2020 | ||
| 500 | |a Date Revised 25.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Thorac Cardiovasc Surg. 2019 Jul;158(1):311-312. - PMID 30876664 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: Atrial fibrillation (AF) is a common complication after esophagectomy and is associated with symptoms, hemodynamic instability, prolonged hospital stay, and an increased incidence of mortality. Our objective was to determine the efficacy and safety of intravenous amiodarone for prophylaxis of postesophagectomy AF | ||
| 520 | |a METHODS: In this retrospective cohort study, 309 patients who underwent esophagectomy formed the initial cohort. Following propensity score-matching, 110 patients who received prophylactic amiodarone 43.75 mg/hour via continuous intravenous infusion over 96 hours (total dose, 4200 mg) were matched to a control group of patients who did not undergo amiodarone prophylaxis (n = 110). The propensity score was obtained using a multivariate logistic regression model with amiodarone as the variable and the following covariates: age, sex, surgical approach, history of neoadjuvant chemotherapy and/or radiation, chronic obstructive pulmonary disease, heart failure, cardiovascular disease, alcohol use (>7 drinks/week), preadmission β-blockers discontinued during hospitalization, preoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, preoperative use of corticosteroids, postoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, postoperative use of corticosteroids, postoperative use of statins, and preoperative Charlson comorbidity index | ||
| 520 | |a RESULTS: The incidence of AF requiring treatment due to rapid ventricular rate and symptoms was lower in the amiodarone group (17 out of 110 [15.5%] vs 32 out of 110 [29.1%]; odds ratio, 0.45; 95% confidence interval, 0.23-0.86; P = .015). There were no significant differences between the groups in median postoperative length of hospital stay, incidence of pulmonary complications, or mortality. The incidences of hypotension requiring treatment (42.7% vs 21.8%; P = .001), bradycardia (8.2% vs 0.0%; P = .002), and corrected QT interval prolongation (10.9% vs 0.0%; P ≤ .0001) were significantly higher in the amiodarone group | ||
| 520 | |a CONCLUSIONS: Prophylactic intravenous amiodarone is associated with a reduction in the incidence of AF following esophagectomy, but is not associated with shorter postoperative length of hospital stay. Intravenous amiodarone for prophylaxis of postesophagectomy AF is associated with hypotension, bradycardia, and corrected QT interval prolongation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a amiodarone | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a esophagectomy | |
| 650 | 4 | |a propensity score | |
| 650 | 4 | |a prophylaxis | |
| 650 | 7 | |a Anti-Arrhythmia Agents |2 NLM | |
| 650 | 7 | |a Amiodarone |2 NLM | |
| 650 | 7 | |a N3RQ532IUT |2 NLM | |
| 700 | 1 | |a Jaynes, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Matthew R |e verfasserin |4 aut | |
| 700 | 1 | |a Corya, Andi L |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Changyu |e verfasserin |4 aut | |
| 700 | 1 | |a Kesler, Kenneth A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of thoracic and cardiovascular surgery |d 1959 |g 158(2019), 1 vom: 04. Juli, Seite 301-310.e1 |w (DE-627)NLM000033510 |x 1097-685X |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2019 |g number:1 |g day:04 |g month:07 |g pages:301-310.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtcvs.2019.01.095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2019 |e 1 |b 04 |c 07 |h 301-310.e1 | ||